EuroNanoMed, an European funding program under the European Commission’s ERA-Net scheme for the advancement of transnational nanomedicine research, has declared that eight projects were selected through its third and final joint transnational call for partnership research projects will get the €8 million fund offered by the funding agencies of EuroNanoMed.
The eight collaborative research projects, engaging 40 partners from 11 nations, were selected from 41 applications engaging 207 partners from 20 European Union member nations. In January 2011, the ERA-Net EuroNanoMed introduced the third joint transnational call to support interdisciplinary and transnational nanomedicine research.
This last call emphasizes the three key nanomedicine subfields, regenerative medicine, targeted delivery systems and diagnostics. External referees reviewed the applications based on their commercial, clinical, technical and scientific merits and then an international peer review panel evaluated them. The eight projects to be funded cover all three nanomedicine subfields and various medical problems, including degenerative skeletal disorders, bone fractures, multifactorial psychiatric disease, amyloid diseases and cancer.
The Chair of the Executive Board and Coordinator of ERA-Net EuroNanoMed, Dr. Virginie Sivan stated that EuroNanoMed has turned out to be a familiar funding program in the nanomedicine field via its three calls for proposals introduced between 2009 and 2011. At present, the partners of EuroNanoMed are involved in the preparation of a second ERA-Net, as EuroNanoMed will be ended in December 2011, he added.